Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.36 |
| ▸ | HTR6 | P50406 | 3/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8796023 | 0.86 | FABP4 (0.43) | BRD4ATAD2DRD1GRIN2BFABP4 | |
| SCHEMBL14916493 | 0.81 | SIRT1 (0.52) | SIRT1HTR2A | |
| SCHEMBL2823313 | 0.81 | PIN1 (0.49) | SIRT1PIN1HTR2A | |
| SCHEMBL14915975 | 0.81 | SIRT1 (0.47) | SIRT1PIN1DRD1ACHEDRD2 | |
| SCHEMBL4872494 | 0.79 | BRD4 (0.37) | BRD4ATAD2HTR6DRD1ACHE | |
| SCHEMBL2825083 | 0.78 | MTNR1A (0.54) | — | |
| SCHEMBL29528570 | 0.77 | PIN1 (0.58) | SIRT1PIN1 | |
| SCHEMBL643577 | 0.77 | PIN1 (0.58) | SIRT1PIN1 | |
| SCHEMBL2475968 | 0.77 | PIN1 (0.58) | SIRT1PIN1 | |
| SCHEMBL176930 | 0.77 | PIN1 (0.58) | SIRT1PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767907-B2 | FOR THERAPY OF PSYCHIC AND NEUROLOGIC DISORDERS | H. LUNDBECK A/S (DK) | 2004-07-27 | — | — | US | disclosed |
| US-6743808-B1 | PSYCHOLOGICAL AND NEUROLOGIC DISORDERS; CENTRAL SEROTONERGIC 5-HT1A AND 5-HT2A RECEPTOR ANTAGONISTS | H. LUNDBECK A/S (DK) | 2004-06-01 | — | — | US | disclosed |
| US-20030195356-A1 | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines | PERREGAARD JENS KRISTIAN (DK) | 2003-10-16 | — | — | US | disclosed |
| US-6218394-B1 | FOR THERAPY OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, SUCH AS GENERALISED ANXIETY DISORDER, PANIC DISORDER | H. LUNDBECK A/S (DK) | 2001-04-17 | — | — | US | disclosed |
| EP-0765311-B1 | 4-ARYL-1-(INDANMETHYL, DIHYDROBENZOFURANMETHYL OR DIHYDROBENZOTHIOPHENEMETHYL)PIPERIDINES, TETRAHYDROPYRIDINES OR PIPERAZINES | LUNDBECK & CO AS H (DK) | 2000-10-04 | — | — | EP | disclosed |
| US-5972964-A | FOR TREATMENT OF CERTAIN PSYCHIC AND NEUROLOGIC DISORDERS SUCH AS PSYCHOSIS, ANXIETY DISORDERS, PANIC DISORDER, OBSESSIVE COMPULSIVE DISORDER, DEPRESSION, IMPULSE CONTROL DISORDERS, ALCOHOL ABUSE, AGGRESSION | H. LUNDBECK A/S (DK) | 1999-10-26 | — | — | US | disclosed |
| US-5807889-A | PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | H. LUNDBECK A/S (DK) | 1998-09-15 | — | — | US | disclosed |
| EP-0673360-B1 | AMINOMETHYLINDANS, -BENZOFURANES AND -BENZOTHIOPHENES | LUNDBECK & CO AS H (DK) | 1998-08-26 | — | — | EP | disclosed |
| EP-0765311-A1 | 4-ARYL-1-(INDANMETHYL, DIHYDROBENZOFURANMETHYL OR DIHYDROBENZOTHIOPHENEMETHYL)PIPERIDINES, TETRAHYDROPYRIDINES OR PIPERAZINES | H. LUNDBECK A/S (DK) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995033721-A1 | 4-ARYL-1-(INDANMETHYL, DIHYDROBENZOFURANMETHYL OR DIHYDROBENZOTHIOPHENEMETHYL)PIPERIDINES, TETRAHYDROPYRIDINES OR PIPERAZINES | H. LUNDBECK A/S (DK) | 1995-12-14 | — | — | WO | disclosed |
| EP-0673360-A1 | AMINOMETHYLINDANS, -BENZOFURANES AND -BENZOTHIOPHENES | H. LUNDBECK A/S (DK) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994013620-A1 | AMINOMETHYLINDANS, -BENZOFURANES AND -BENZOTHIOPHENES | H. LUNDBECK A/S (DK) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195356-A1 | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines | CNR1, TPH1, CNR2 | BRD4 1083/4885ATAD2 1466/4885SIRT1 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.